Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
Breast cancer
Clipped node
Neoadjuvant chemotherapy
Sentinel lymph node surgery
Targeted axillary dissection
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
11
04
2024
accepted:
24
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
For patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NAC), retrieving previously clipped, biopsy-proven positive lymph nodes during sentinel lymph node biopsy [i.e., targeted axillary dissection (TAD)] may reduce false negative rates. However, the overall utilization and impact of clipping positive nodes remains uncertain. We retrospectively analyzed cN+ ISPY-2 patients (2011-2022) undergoing axillary surgery after NAC. We evaluated trends in node clipping and associations with type of axillary surgery [sentinel lymph node (SLN) only, SLN and axillary lymph node dissection (ALND), or ALND only] and event-free survival (EFS) in patients that were cN+ on a NAC trial. Among 801 cN+ patients, 161 (20.1%) had pre-NAC clip placement in the positive node. The proportion of patients that were cN+ undergoing clip placement increased from 2.4 to 36.2% between 2011 and 2021. Multivariable logistic regression showed nodal clipping was independently associated with higher odds of SLN-only surgery [odds ratio (OR) 4.3, 95% confidence interval (CI) 2.8-6.8, p < 0.001]. This was also true among patients with residual pathologically node-positive (pN+) disease. Completion ALND rate did not differ based on clip retrieval success. No significant differences in EFS were observed in those with or without clip placement, both with or without successful clip retrieval [hazard ratio (HR) 0.85, 95% CI 0.4-1.7, p = 0.7; HR 1.8, 95% CI 0.5-6.0, p = 0.3, respectively]. Clip placement in the positive lymph node before NAC is increasingly common. The significant association between clip placement and omission of axillary dissection, even among patients with pN+ disease, suggests a paradigm shift toward TAD as a definitive surgical management strategy in patients with pN+ disease after NAC.
Sections du résumé
BACKGROUND
BACKGROUND
For patients with clinically node-positive (cN+) breast cancer undergoing neoadjuvant chemotherapy (NAC), retrieving previously clipped, biopsy-proven positive lymph nodes during sentinel lymph node biopsy [i.e., targeted axillary dissection (TAD)] may reduce false negative rates. However, the overall utilization and impact of clipping positive nodes remains uncertain.
PATIENTS AND METHODS
METHODS
We retrospectively analyzed cN+ ISPY-2 patients (2011-2022) undergoing axillary surgery after NAC. We evaluated trends in node clipping and associations with type of axillary surgery [sentinel lymph node (SLN) only, SLN and axillary lymph node dissection (ALND), or ALND only] and event-free survival (EFS) in patients that were cN+ on a NAC trial.
RESULTS
RESULTS
Among 801 cN+ patients, 161 (20.1%) had pre-NAC clip placement in the positive node. The proportion of patients that were cN+ undergoing clip placement increased from 2.4 to 36.2% between 2011 and 2021. Multivariable logistic regression showed nodal clipping was independently associated with higher odds of SLN-only surgery [odds ratio (OR) 4.3, 95% confidence interval (CI) 2.8-6.8, p < 0.001]. This was also true among patients with residual pathologically node-positive (pN+) disease. Completion ALND rate did not differ based on clip retrieval success. No significant differences in EFS were observed in those with or without clip placement, both with or without successful clip retrieval [hazard ratio (HR) 0.85, 95% CI 0.4-1.7, p = 0.7; HR 1.8, 95% CI 0.5-6.0, p = 0.3, respectively].
CONCLUSION
CONCLUSIONS
Clip placement in the positive lymph node before NAC is increasingly common. The significant association between clip placement and omission of axillary dissection, even among patients with pN+ disease, suggests a paradigm shift toward TAD as a definitive surgical management strategy in patients with pN+ disease after NAC.
Identifiants
pubmed: 38995451
doi: 10.1245/s10434-024-15792-x
pii: 10.1245/s10434-024-15792-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Bland KI, Scott-Conner CE, Menck H, Winchester DP. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg. 1999;188(6):586–95. https://doi.org/10.1016/s1072-7515(99)00056-3 .
doi: 10.1016/s1072-7515(99)00056-3
pubmed: 10359351
Khafagy M, Mostafa A, Fakhr I. Distribution of axillary lymph node metastases in different levels and groups in breast cancer, a pathological study. J Egyptian Natl Cancer Instit. 2011;23(1):25–30. https://doi.org/10.1016/j.jnci.2011.07.004 .
doi: 10.1016/j.jnci.2011.07.004
Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–63. https://doi.org/10.1200/jco.2006.07.4062 .
doi: 10.1200/jco.2006.07.4062
pubmed: 17485711
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33. https://doi.org/10.1016/S1470-2045(10)70207-2 .
doi: 10.1016/S1470-2045(10)70207-2
pubmed: 20863759
pmcid: 3041644
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53. https://doi.org/10.1056/NEJMoa012782 .
doi: 10.1056/NEJMoa012782
pubmed: 12904519
Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983–90. https://doi.org/10.1016/s1470-2045(06)70947-0 .
doi: 10.1016/s1470-2045(06)70947-0
pubmed: 17138219
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial. Ann Surg. 2010;252(3):426–33.
doi: 10.1097/SLA.0b013e3181f08f32
pubmed: 20739842
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030 .
doi: 10.6004/jnccn.2022.0030
Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558–66. https://doi.org/10.1097/SLA.0b013e3181b8fd5e .
doi: 10.1097/SLA.0b013e3181b8fd5e
pubmed: 19730235
Boughey JC, Yu H, Dugan CL, et al. Changes in surgical management of the axilla over 11 years—report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30(11):6401–10. https://doi.org/10.1245/s10434-023-13759-y .
doi: 10.1245/s10434-023-13759-y
pubmed: 37380911
Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS One. 2016;11(9):e0162605. https://doi.org/10.1371/journal.pone.0162605 .
doi: 10.1371/journal.pone.0162605
pubmed: 27606623
pmcid: 5015960
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61. https://doi.org/10.1001/jama.2013.278932 .
doi: 10.1001/jama.2013.278932
pubmed: 24101169
pmcid: 4075763
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64. https://doi.org/10.1200/jco.2014.55.7827 .
doi: 10.1200/jco.2014.55.7827
pubmed: 25452445
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18. https://doi.org/10.1016/s1470-2045(13)70166-9 .
doi: 10.1016/s1470-2045(13)70166-9
pubmed: 23683750
Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802–7. https://doi.org/10.1097/sla.0000000000001375 .
doi: 10.1097/sla.0000000000001375
pubmed: 26649589
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072–8. https://doi.org/10.1200/jco.2015.64.0094 .
doi: 10.1200/jco.2015.64.0094
pubmed: 26811528
pmcid: 4933133
Kuemmel S, Heil J, Bruzas S, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158(8):807–15. https://doi.org/10.1001/jamasurg.2023.1772 .
doi: 10.1001/jamasurg.2023.1772
pubmed: 37285140
pmcid: 10248815
Montagna G, Lee MK, Sevilimedu V, Barrio AV, Morrow M. Is nodal clipping beneficial for node-positive breast cancer patients receiving neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29(10):6133–9. https://doi.org/10.1245/s10434-022-12240-6 .
doi: 10.1245/s10434-022-12240-6
pubmed: 35902495
pmcid: 10109537
Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy—a rare event. JAMA Oncol. 2021;7(12):1851–5. https://doi.org/10.1001/jamaoncol.2021.4394 .
doi: 10.1001/jamaoncol.2021.4394
pubmed: 34617979
Boughey JC, Alvarado MD, Lancaster RB, et al. Surgical standards for management of the axilla in breast cancer clinical trials with pathological complete response endpoint. NPJ Breast Cancer. 2018;4:26. https://doi.org/10.1038/s41523-018-0074-6 .
doi: 10.1038/s41523-018-0074-6
pubmed: 30131975
pmcid: 6098077
Siso C, de Torres J, Esgueva-Colmenarejo A, et al. Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA Trial): A new tool to guide the excision of the clipped node after neoadjuvant treatment. Ann Surg Oncol. 2018;25(3):784–91. https://doi.org/10.1245/s10434-017-6270-z .
doi: 10.1245/s10434-017-6270-z
pubmed: 29197044
Mukhtar RA, Chau H, Woriax H, et al. Breast conservation surgery and mastectomy have similar locoregional recurrence after neoadjuvant chemotherapy: results from 1462 patients on the prospective, randomized I-SPY2 trial. Ann Surg. 2023;278(3):320–7. https://doi.org/10.1097/sla.0000000000005968 .
doi: 10.1097/sla.0000000000005968
pubmed: 37325931
Heidinger M, Knauer M, Tausch C, Weber WP. Tailored axillary surgery—A novel concept for clinically node positive breast cancer. Breast. 2023;69:281–9. https://doi.org/10.1016/j.breast.2023.03.005 .
doi: 10.1016/j.breast.2023.03.005
pubmed: 36922305
pmcid: 10034500
Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19(1):667. https://doi.org/10.1186/s13063-018-3021-9 .
doi: 10.1186/s13063-018-3021-9
pubmed: 30514362
pmcid: 6278139
Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024. https://doi.org/10.1001/jamaoncol.2024.0578 .
doi: 10.1001/jamaoncol.2024.0578
pubmed: 38662396
Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101). Breast. 2021;60:98–110. https://doi.org/10.1016/j.breast.2021.09.004 .
doi: 10.1016/j.breast.2021.09.004
pubmed: 34555676
pmcid: 8463904
Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27(12):4795–801. https://doi.org/10.1245/s10434-020-08900-0 .
doi: 10.1245/s10434-020-08900-0
pubmed: 32779055
Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804–12. https://doi.org/10.1016/j.ejso.2020.10.014 .
doi: 10.1016/j.ejso.2020.10.014
pubmed: 33092968
Guergan S, Hoopmann U, Roehm C, et al. Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axilla. Arch Gynecol Obstet. 2021;304(3):839–48. https://doi.org/10.1007/s00404-021-06085-9 .
doi: 10.1007/s00404-021-06085-9
pubmed: 34142225
pmcid: 8325667